Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity for production of hormones and vasoactive peptides. Because of their perceived rarity, NETs have not historically been a focus of rigorous clinical research. However, the diagnosed incidence of NETs has been increasing, and the estimated prevalence in the United States exceeds 100,000 individuals. The recent completion of several phase III studies, including those evaluating octreotide, sunitinib, and everolimus, has demonstrated that rigorous evaluation of novel agents in this disease is both feasible and can lead to practice-changing outcomes. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trials planning meeting to identify key unmet needs, develop appropriate study end points, standardize clinical trial inclusion criteria, and formulate priorities for future NET studies for the US cooperative group program. Emphasis was placed on the development of well-designed clinical trials with clearly defined efficacy criteria. Key recommendations include the evaluation of pancreatic NET separately from NETs of other sites and the exclusion of patients with poorly differentiated histologies from trials focused on low-grade histologies. Studies evaluating novel agents for the control of hormonal syndromes should avoid somatostatin analog washout periods when possible and should include quality-of-life end points. Because of the observed long survival after progression of many patients, progression-free survival is recommended as a feasible and relevant primary end point for both phase III studies and phase II studies where a delay in progression is expected in the absence of radiologic responses.
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Matthew H
MH
Kulke
Lillian L
LL
Siu
Joel E
JE
Tepper
George
G
Fisher
Deborah
D
Jaffe
Daniel G
DG
Haller
Lee M
LM
Ellis
Jacqueline K
JK
Benedetti
Emily K
EK
Bergsland
Timothy J
TJ
Hobday
Eric
E
Van Cutsem
James
J
Pingpank
Kjell
K
Oberg
Steven J
SJ
Cohen
Mitchell C
MC
Posner
James C
JC
Yao
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D054547:National Cancer Institute (U.S.); D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States
J Clin Oncol. 2008 Jun 20;26(18):3063-72
18565894
Ann Oncol. 2019 Dec 1;30(12):2010
31406974
Endocr Relat Cancer. 2007 Jun;14(2):483-92
17639061
J Clin Oncol. 2008 Apr 20;26(12):1922-3
18421044
Cancer. 2005 Oct 15;104(8):1590-602
16134179
Am J Clin Oncol. 2008 Jun;31(3):271-9
18525307
J Clin Oncol. 2008 Jul 10;26(20):3403-10
18612155
Genes Chromosomes Cancer. 2008 Jul;47(7):591-603
18383209
Cancer. 2008 Sep 1;113(5):921-9
18618495
N Engl J Med. 1986 Sep 11;315(11):663-6
2427948
Genes Chromosomes Cancer. 2008 Jan;47(1):84-92
17943967
J Clin Oncol. 2008 Mar 10;26(8):1316-23
18323556
Endocr Relat Cancer. 2003 Dec;10(4):437-50
14713256
Digestion. 2000;62 Suppl 1:33-8
10940685
J Clin Oncol. 2010 Apr 1;28(10):1652-9
20194865
Clin Cancer Res. 2009 Jan 1;15(1):338-45
19118063
J Clin Oncol. 2008 May 1;26(13):2124-30
18445841
J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9
19903805
Br J Radiol. 2001 Nov;74(887):1065-70
11709476
AJR Am J Roentgenol. 2003 Jan;180(1):121-8
12490490
Eur J Nucl Med. 2001 Sep;28(9):1421-9
11585303
Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):595-616
16183530
Am J Transplant. 2008 Jun;8(6):1205-13
18444921
Ann Oncol. 1997 Jul;8(7):685-90
9296223
Virchows Arch. 2006 Oct;449(4):395-401
16967267
J Clin Oncol. 2002 May 1;20(9):2388-99
11981013
J Clin Oncol. 2004 Dec 1;22(23):4762-71
15570077
J Clin Oncol. 2008 Sep 10;26(26):4311-8
18779618
Cancer. 2003 Feb 15;97(4):934-59
12569593
J Clin Oncol. 2008 Aug 1;26(22):3791-6
18669467
J Clin Oncol. 2010 Jan 1;28(1):69-76
19933912
Virchows Arch. 2007 Oct;451(4):757-62
17674042
Surg Oncol Clin N Am. 2003 Jan;12(1):231-42
12735141
J Natl Compr Canc Netw. 2009 Jul;7(7):760-4
19635228
Am J Clin Pathol. 2009 Feb;131(2):206-21
19141381
J Clin Oncol. 2007 May 20;25(15):2122-6
17513819
N Engl J Med. 1992 Feb 20;326(8):519-23
1310159
Eur J Cancer. 2006 Mar;42(4):477-84
16412628
Cancer. 2000 Feb 15;88(4):770-6
10679645
J Clin Oncol. 2009 Oct 1;27(28):4656-63
19704057